U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Ca.2H3O4Si
Molecular Weight 230.292
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CALCIUM SILICATE

SMILES

[Ca++].O[Si](O)(O)[O-].O[Si](O)(O)[O-]

InChI

InChIKey=LECAAGVQUHQAJK-UHFFFAOYSA-N
InChI=1S/Ca.2H3O4Si/c;2*1-5(2,3)4/h;2*1-3H/q+2;2*-1

HIDE SMILES / InChI
Molecular Formula H4O4Si
Molecular Weight 96.1149
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
511
Unknown

Approved Use

Unknown
Palliative
Phase I
438
Unknown

Approved Use

Unknown
Palliative
Phase I
438
Unknown

Approved Use

Unknown
Primary
Approved
8583
Unknown

Approved Use

Hypocalcemia, chronic (treatment) ā€” Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
2015-09-16
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.
2014-07
Effect of calcium phosphate and vitamin Dā‚ƒ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.
2014-01-17
A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans.
2012-04
Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity.
2009-07-02
Henri Moissan: winner of the Nobel Prize for Chemistry 1906.
2006-10-20
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate].
2006-10
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.
2003-01
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.
2002-12
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.
2002-11-04
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors.
2002-09-15
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.
2002-09-06
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.
2002-09-06
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.
2002-09
Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent.
2002-07-05
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones.
2002-07
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
2002-07
Expression of functional CCR and CXCR chemokine receptors in podocytes.
2002-06-15
Human kidney diamine oxidase: heterologous expression, purification, and characterization.
2002-06
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002-05-15
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.
2002-04-19
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice.
2002-03-15
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor.
2002-03
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart.
2002-03
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3.
2002-02-01
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.
2002-02
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.
2002-02
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
2002-01-15
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.
2002
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.
2001-12-21
Complement activation in factor D-deficient mice.
2001-12-04
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.
2001-11-30
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.
2001-11-01
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.
2001-11
Activating mutations of the calcium-sensing receptor: management of hypocalcemia.
2001-11
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.
2001-11
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
2001-10-26
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels.
2001-10-12
Microarray analysis of differential gene expression in lead-exposed astrocytes.
2001-10-01
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
2001-10
Familial intrahepatic cholestasis 1: studies of localization and function.
2001-10
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein.
2001-09-15
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.
2001-09-07
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.
2001-09-01
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.
2001-09
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.
2001-09
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.
2001-08-28
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.
2001-08
[Acute renal failure caused by hypercalcemia].
2001-06-10
Studies on the calcemic effect of intravenous secretin in humans.
1975-06
Patents

Patents

03966773
135
03974176
92
03981818
90
04008309
67
04028407
65
04041173
65
04042702
90
04058507
65
04063023
65
06485737
65
06497902
65
08637538
65
20090030026
65
20130174651
65
JP2017071731
65
US2143359
65

Sample Use Guides

In Vivo Use Guide
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:20:54 GMT 2025
Edited
by admin
on Mon Mar 31 18:20:54 GMT 2025
Record UNII
S4255P4G5M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIUM SILICATE
FCC   HSDB   II   INCI   MART.   MI   VANDF   WHO-DD  
INCI  
Official Name English
CALCAREA SILICATA
HPUS  
Preferred Name English
INS-552
Code English
CALCAREA SILICATA [HPUS]
Common Name English
CALCIUM SILICATE [MI]
Common Name English
CALCIUM SILICATE [MART.]
Common Name English
CALCIUM SILICATE [FCC]
Common Name English
SILICIC ACID, CALCIUM SALT
Common Name English
Calcium silicate [WHO-DD]
Common Name English
CALCIUM SILICATE [HSDB]
Common Name English
E-552
Common Name English
CALCIUM SILICATE [VANDF]
Common Name English
E552
Common Name English
HUBERDERM 1000
Common Name English
INS NO.552
Code English
CALCIUM SILICATE [II]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 178.3297
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
WHO-VATC QA02AC02
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
JECFA EVALUATION INS-552
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-552
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
EPA PESTICIDE CODE 72607
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
DSLD 2689 (Number of products:4)
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
WHO-ATC A02AC02
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
CFR 21 CFR 582.2227
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
CFR 21 CFR 176.170
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
CFR 21 CFR 172.410
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
215-710-8
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
DRUG BANK
DB13829
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
DRUG CENTRAL
4837
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
MERCK INDEX
m2974
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY Merck Index
HSDB
705
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
NCI_THESAURUS
C80919
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
WIKIPEDIA
CALCIUM SILICATE
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
CAS
1344-95-2
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
MESH
C031293
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
PUBCHEM
73415800
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
SMS_ID
100000078526
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
EVMPD
SUB12473MIG
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
DAILYMED
S4255P4G5M
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
RXCUI
1311526
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID4029648
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108942
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
NCI_THESAURUS
C45678
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
CONCEPT Industrial Aid
FDA UNII
S4255P4G5M
Created by admin on Mon Mar 31 18:20:54 GMT 2025 , Edited by admin on Mon Mar 31 18:20:54 GMT 2025
PRIMARY
Related Record Type Details
Structure of ORTHOSILICIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CALCIUM CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 ā€¢ 301-594-8966